Clinical Trials at Ellis Fischel Cancer Center: (573) 882-7440

What are clinical trials?
Clinical trials are reserach studies that involve people. They are the final step in a long process that begins with research in a lab and animal testing.  Many treatments used today are the result of past clinical trials.

In cancer, clinical trials are designed to answer questions about new ways to:

• Treat Cancer
• Find and diagnose cancer
• Prevent cancer
• Manage symptoms of cancer or side effects from its treatment

Studies are designed to answer questions about new treatments or ways of using an existing treatment better.  These trials test many types of treatments, such as new:

• Drugs or vaccines
• Ways to do surgery or give radiation therapy
• Combinations of treatments

Please visit the following link for more information from the National Cancer Institute (NCI) about Clinical Trials:  http://www.cancer.gov/clinicaltrials/learningabout

Ellis Fischel Cancer Center physicians and staff ensure that all of our patients receive the best care. This means if we ask you or a loved one to participate in a clinical trial, we have good reason to believe thaat the new treatment(s) will help and we see promise and potential in the new treatment options. These new treatments could become the new standard of care and we want only the best for our patients. 

Watch Dr. Freter and our clinical trial manager Cheryl Victor to learn more about clinical trials at Ellis Fischel Cancer Center.

Breast Cancer

Adjuvant

• A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-positive Primary Breast Cancer
http://clinicaltrials.gov/show/NCT01358877

• Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophgosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=727332&protocolsearchid=10395403&version=patient

• Phase III Randomized Study of Adjuvant Chemotherapy With Versus Without Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=692574&version=HealthProfessional&protocolsearchid=10005957

• Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=692475&version=HealthProfessional&protocolsearchid=10005960

Ductal Carcinoma In Situ

• Phase III Randomized Study of Radiotherapy With Versus Without Trastuzumab (Herceptin®) in Women With HER2-Positive Ductal Carcinoma In Situ Who Underwent Lumpectomy
http://www.cancer.gov/clinicaltrials/search/view?cdrid=615085&version=HealthProfessional&protocolsearchid=10005948

Neo Adjuvant

• Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=659382&version=HealthProfessional&protocolsearchid=10005958

• Phase II Randomized Study of Neoadjuvant Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin Hydrochloride, Cyclophosphamide, and Pegfilgrastim With Versus Without Bevacizumab in Women With HER2/neu-Negative Inflammatory or Locally
Advanced Breast Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=636131&version=HealthProfessional&protocolsearchid=10005962

Metastatic

• Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=669300&version=Patient&protocolsearchid=10395407

• A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
http://www.cancer.gov/clinicaltrials/featured/trials/ECOG-E2108

Prevention

• Vitamin D and Breast Cancer Biomarkers
http://www.cancer.gov/clinicaltrials/search/view?cdrid=687263&version=HealthProfessional

Gastrointestinal (GI) Cancer

Colon

• Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=696891&version=HealthProfessional&protocolsearchid=10005988

• Phase III Randomized Study of Adjuvant FOLFOX Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Celecoxib in Patients With Resected Stage III Colon Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=675693&version=HealthProfessional&protocolsearchid=8627733

• Phase III Randomized Study of mFOLFOX7 or XELOX Plus Bevacizumab Versus Fluorouracil/Leucovorin Calcium or Capecitabine Plus Bevacizumab as First-Line Therapy in Elderly Patients With Metastatic Colorectal Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=692257&version=HealthProfessional&protocolsearchid=10006002

Liver

• Phase III Randomized Study of Sorafenib Tosylate With Versus Without Doxorubicin Hydrochloride in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=659348&version=HealthProfessional&protocolsearchid=8698077

Pancreatic

• Phase II Randomized Study of Everolimus With Versus Without Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
http://www.cancer.gov/clinicaltrials/search/view?cdrid=687459&version=HealthProfessional&protocolsearchid=10006006

• Phase III Randomized Study of Adjuvant Gemcitabine Hydrochloride With Versus Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With Versus Without Chemoradiotherapy With Either Capecitabine or Fluorouracil in Patients With Resected Head of Pancreas Adenocarcinoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=659092&version=HealthProfessional&protocolsearchid=10006007

• Immunotherapy Study for Surgically Resected Pancreatic Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=666728&version=HealthProfessional&protocolsearchid=10006022

Rectal

• Phase II/III Randomized Study of Neoadjuvant FOLFOX Therapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Versus Chemoradiation Comprising Fluorouracil or Capecitabine, and Radiation Therapy in Patients With Locally Advanced Rectal Cancer Undergoing Low-Anterior Resection With Total Mesorectal Excision
http://www.cancer.gov/clinicaltrials/search/view?cdrid=715321&version=HealthProfessional&protocolsearchid=10310298

• Phase III Randomized Study of Laparoscopic-Assisted Resection Versus Open Resection in Patients With Stage IIA, IIIA, or IIIB Rectal Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=601816&version=HealthProfessional&protocolsearchid=10310300 

Prostate

• Phase III Trial of Dose Excalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men With High Risk Prostate Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=727326&version=HealthProfessional&protocolsearchid=6660815

• A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
http://www.clinicaltrial.gov/ct2/show/NCT01338012?term=p10-1&rank=1

Renal

• Phase III Randomized Study of Everolimus With Versus Without Bevacizumab in Patients With Advanced Renal Cell Carcinoma That Progressed After First-Line Treatment With Tyrosine Kinase Inhibitors
http://www.cancer.gov/clinicaltrials/search/view?cdrid=684313&version=HealthProfessional&protocolsearchid=8837020

• Phase III Randomized Study of Gemcitabine Hydrochloride and Cisplatin With Versus Without Bevacizumab in Patients With Advanced Transitional Cell Carcinoma of the Urinary Tract
http://www.cancer.gov/clinicaltrials/search/view?cdrid=649174&version=HealthProfessional&protocolsearchid=10310319

Cervical

• Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
http://www.cancer.gov/clinicaltrials/search/view?cdrid=670125&version=HealthProfessional&protocolsearchid=10006064

Gynecological Cancer

Endometrial

• Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=629591&version=HealthProfessional&protocolsearchid=10006070

• Phase III Randomized Study of Adjuvant Chemoradiotherapy Comprising Cisplatin and Tumor Volume-Directed Radiotherapy Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients With Stage I-IVA Endometrial Carcinoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=649079&version=HealthProfessional&protocolsearchid=10006077

Miscellaneous

• Phase III Randomized Study of Paclitaxel Versus Polyglutamate Paclitaxel as Consolidation/Maintenance Therapy Versus No Further Anticancer Therapy Until Disease Progression in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer or Fallopian Tube Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=422427&version=HealthProfessional&protocolsearchid=10006073

• Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer http://www.cancer.gov/clinicaltrials/search/view?cdrid=546714&version=HealthProfessional&protocolsearchid=10006074

• Phase III Randomized Study of Paclitaxel With Carboplatin Versus Ifosfamide in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV Persistent or Recurrent Uterine or Ovarian Carcinosarcoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=651458&version=HealthProfessional&protocolsearchid=10006081

• Phase III Randomized Study of Platinum-Containing Chemotherapy With Versus Without Bevacizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
http://www.cancer.gov/clinicaltrials/search/view?cdrid=582533&version=HealthProfessional&protocolsearchid=10006087 

Lung Cancer

Non-Small Cell Lung Cancer

• Phase III Randomized Study of Sunitinib Malate as Maintenance Therapy in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Combination Chemotherapy
http://www.cancer.gov/clinicaltrials/search/view?cdrid=597649&version=HealthProfessional&protocolsearchid=10006145

• Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=475774&version=HealthProfessional&protocolsearchid=10006151

• Phase III Docetaxel & Ramucirumab vs Docetaxel & Placebo in the Second Line treatment of Stage IV NSCLC
http://www.cancer.gov/clinicaltrials/search/view?cdrid=682572&version=HealthProfessional&protocolsearchid=10006153

• Phase III Randomized Study of Gemcitabine Hydrochloride or Pemetrexed Disodium in Combination With Carboplatin With Versus Without Celecoxib in Patients With COX-2-Expressing Advanced Non-Small Cell Lung Cancer
http://www.cancer.gov/clinicaltrials/search/view?cdrid=662707&version=HealthProfessional&protocolsearchid=10310321

Limited-Stage Small Cell Lung Cancer

• Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
http://www.cancer.gov/clinicaltrials/search/view?cdrid=588879&version=HealthProfessional&protocolsearchid=10006155

Skin Cancer

Melanoma

• A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA 4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=692568&version=HealthProfessional

Hematology

Lymphoma

• Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=433265&version=HealthProfessional&protocolsearchid=10006125

• Phase II Randomized Study of Ofatumumab and Bendamustine Hydrochloride With Versus Without Bortezomib in Patients With Untreated Follicular Lymphoma
http://www.cancer.gov/clinicaltrials/search/view?cdrid=694298&version=HealthProfessional&protocolsearchid=10006127

• A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
http://www.cancer.gov/clinicaltrials/search/view?cdrid=688737&version=HealthProfessional&protocolsearchid=10006131